PROSTATE WARRIORS - The latest news about prostate cancer
  • Home
  • Cancer 1O1
  • News
  • TRIALS TABLE
  • Navigator
  • Newsletters
  • BATcave
  • tE2 Initiative
  • Contact
  • Search
  • Menu Menu
  • X

BRL-302 Phase 1: A New CAR-T Cells Therapy for mCRPC

June 17, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-06-17 10:27:352025-06-17 10:27:35BRL-302 Phase 1: A New CAR-T Cells Therapy for mCRPC

Phase 1 Trial: PMR-116, Targeting The Undruggable MYC Oncogene

June 16, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-06-16 08:47:552025-06-16 08:47:55Phase 1 Trial: PMR-116, Targeting The Undruggable MYC Oncogene

UPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent

June 12, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-06-12 08:48:282025-06-12 08:48:28UPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent

Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials

June 11, 2025/in Clinical Trial, Metastatic, Phase 1, Phase 2/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-06-11 10:59:142025-06-11 11:05:24Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials

Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors

June 5, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-06-05 15:18:372025-06-05 15:18:37Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors

UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC

June 5, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-06-05 12:47:122025-06-05 12:47:12UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC

UPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC

May 29, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-05-29 08:51:022025-05-29 08:51:02UPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC

Phase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

May 29, 2025/in Clinical Trial, Metastatic, Phase 1, Phase 2/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-05-29 07:36:272025-05-29 07:36:27Phase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

Phase 1 Study Results of JNJ-78278343 (pasritamig) in mCRPC

May 23, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-05-23 13:01:122025-05-23 13:01:12Phase 1 Study Results of JNJ-78278343 (pasritamig) in mCRPC

Phase 1/2 Trial: 177Lu-NYM032 Shows Efficacy In mCRPC

May 23, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-05-23 12:24:182026-09-01 11:09:43Phase 1/2 Trial: 177Lu-NYM032 Shows Efficacy In mCRPC
Page 17 of 25«‹1516171819›»

Menu

  • Home
  • Cancer 1O1
  • News
  • TRIALS TABLE
  • Navigator
  • Newsletters
  • BATcave
  • tE2 Initiative
  • Contact

Categories

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • September 2023

Project Navigator


Let's try to finance it!

A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.

Tags

177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy

Latest Posts

  • Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
  • UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
  • UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
  • UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
© Copyright 2024 - 2026 PROSTATE WARRIORS - The latest news about prostate cancer - Supporters' Hall
  • X
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only